PEN
$288.94
Penumbra
$8.33
2.97%
PEN
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  $0.10
Revenue:  N/A
Tuesday
May 25
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when PEN reports earnings?
Beat
Meet
Miss

Where is PEN's stock price going from here?
Up
Flat
Down
Stock chart of PEN
Analysts
Summary of analysts' recommendations for PEN
Score
Grade
Pivots
Resistance
$314.04
$307.65
$298.29

$291.90

Support
$282.54
$276.15
$266.79
Tweet
Growth
Description
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.